Teva In Transition: Generics, Specialty And ‘The Space Between’

Teva Pharmaceutical Industries Ltd. is in the midst of making big changes that management believes will position it for sustainable long-term growth. As part of the new strategy, Teva is preparing for the integration of Allergan PLC’s generic drug business, setting up to launch several brand drugs from its newly pruned specialty pipeline, and managing 17 projects in a budding area for the company, new therapeutic entities (NTEs), medicines that bridge generics and specialty.

President-Global R&D Michael Hayden talked about all three areas of Teva’s strategy during an interview at Informa’s Pharmaceutical Strategy Conference in New York Sept. 27.